VEGFA and non-small cell lung carcinoma: Moreover, combination therapies of EGFR-TKIs with anti-VEGF(R) inhibitors or chemotherapy show promise as therapeutics for patients with EGFR-mutated NSCLC to maximize survival [27,28,129].